All In Biotech

Drug Trial Radar · NCT06254326

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 19, 2024

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Oligo Nation, Inc
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.

Conditions

  • Recurrent Oligodendroglioma
  • Progressive Oligodendroglioma

Interventions

  • TTRNA-DC vaccines with GM-CSFBiological

    Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment

  • Autologous Hematopoietic Stem cells (HSCs)Biological

    Participants will receive a single infusion of autologous CD34+ HSCs

  • TTRNA-xALTBiological

    Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells

  • Td vaccineDrug

    All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of enrolled subject who receive qualified immunotherapy investigational product.Time frame: enrollment up to 9 months
  2. Incidence of investigational treatment related severe toxicity (Dose-limiting toxicity event) assessed during the period beginning with administration of ex vivo expanded TTRNA T cells through 6 weeks post infusion.Time frame: enrollment to completion of DLT window; up to 9 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida Health Shands Hospital

    Gainesville, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.